Post-Therapy Leukocytosis Events After Intravenous Aminophylline Compared to the Nebulized Salbutamol in Asthma Exacerbations Patients

Lorensia, Amelia; Ikawati, Zullies; Andayani, Tri Murti; Maranatha, Daniel; Wahjudi, Mariana

doi:10.15416/ijcp.2016.5.3.149

Cited by 4 publications

(3 citation statements)

References 15 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, other effects reported by the studies are less obvious and may impact the patient's condition in more varied ways. The decrease in serum potassium levels (Sahan et al, 2013;Barkiya et al, 2016;Lorensia et al, 2016) is an effect widely reported in past studies (Heianza et al, 2011) and, in fact, this mechanism may be used therapeutically for patients presenting with hyperkalaemia (Viera, 2015). Although potassium is key to ensuring electrical functions such as muscle stimulation and nerve impulses are maintained within suitable limits (Udensi et al, 2017), its change in the short term is not usually problematic.…”

Section: Disruption To the Cardiovascular And Respiratory Systems Can...mentioning

confidence: 90%

Effects of nebulised beta-2 agonists on clinical observations in asthma exacerbations

Mortimer¹,

Nikoletou

Ooms

et al. 2023

Journal of Paramedic Practice

View full text Add to dashboard Cite

Background: Despite concerns over their side effects, short-acting beta-2 agonists are still used in high doses in prehospital care internationally to treat asthma exacerbations. This systematic review set out to identify the physiological effects associated with this treatment and determine their potential impact on the patient's presenting or underlying conditions. Methods: A systematic search of literature published from 2010 to 2020 focusing on asthmatic patients receiving nebulised beta-2 agonists during an acute exacerbation was undertaken and relevant articles reviewed. Findings: Eight out of 897 studies met the inclusion criteria. While the studies were heterogeneous with a range of outcome measures, synthesis showed evidence of bronchodilator action throughout, with reductions in potassium levels and cardiovascular changes reported in several studies. Conclusions: Therapeutic effects demonstrated within the data support the use of nebulised beta-2 agonists in these patients and, while adverse effects are frequently seen in the cardiovascular and endocrine systems, their impact on the patient's overall condition remains unclear.

show abstract

Section: Disruption To the Cardiovascular And Respiratory Systems Can...mentioning

confidence: 90%

Effects of nebulised beta-2 agonists on clinical observations in asthma exacerbations

Mortimer¹,

Nikoletou

Ooms

et al. 2023

Journal of Paramedic Practice

View full text Add to dashboard Cite

show abstract

“…Research by Lorensia et al showed the incidence of side effects in the use of intravenous aminophylline was very rare and was not even found in several hospital patients in Surabaya. 27 …”

Section: Discussionmentioning

confidence: 99%

Patterns of bronchodilator therapy in asthmatic outpatients

Aryani

Rahmawati

Cintyadewi

et al. 2023

J. Public Health Afr.

View full text Add to dashboard Cite

Background: Bronchodilators are used to treat asthma symptoms. The administration of this therapy can be given through monotherapy or in combination to achieve the maximum therapeutic effect. Objective: This study aimed to examine the prescribing pattern of bronchodilators in asthmatic outpatients. Methods: A retrospective study was done by reviewing and analyzing medical records of asthmatic outpatients from January 2019 until December 2020. Data analysis was performed descriptively. Results: In this study, bronchodilators were administered by inhalation 97.4% compared to oral routes 2.6%. Combination bronchodilator therapy showed 54.7% compared to monotherapy by 46.3%. The combination ICS/LABA budesonide/formoterol 160/4.5 mcg was the most widely used 45.7%. Conclusion: The use of a bronchodilator was in accordance with the Global Initiative for Asthma guidelines. The route of drug administration through inhalation is more widely used than oral. Combination bronchodilators were more recommended than bronchodilator monotherapy to control asthma symptoms.

show abstract

“…Beberapa penelitian terdahulu di Indonesia mengenai perbandingan dari efektivitas obat aminofilin dengan salbutamol (obat golongan beta-2 agonis aksi pendek) yang merupakan terapi lini pertama serangan asma, 1,27 hasilnya menunjukkan bahwa efektivitas aminofilin dan salbutamol sebagai standar lini pertama tidak jauh berbeda, 32,33 sedangkan berdasarkan data dari luar negeri, golongan metilsantin (aminofilin dan teofilin) memiliki efektivitas bronkodilator yang lebih rendah daripada salbutamol. Golongan metilsantin digunakan sebagai terapi tambahan dalam manajemen asma apabila efektivitas terapi belum optimal, serta perannya dalam menajemen eksaserbasi asma masih kontroversal.…”

Section: Pembahasanunclassified

Effectiveness and Toxicity Risk of Intravenous Aminophylline in Exacerbation Asthma Treatment

Lorensia

Ikawati

Andayani

et al. 2018

Indones J Clin Pharm

Self Cite

View full text Add to dashboard Cite

4Program Studi Apoteker, Fakultas Farmasi Universitas Surabaya, Surabaya AbstrakAsma merupakan penyakit inflamasi kronis pada saluran pernafasan yang mempunyai prevalensi global yang cukup besar. Perburukan penyakit asma berupa serangan asma yang menyebabkan peningkatan gejala asma dan penurunan fungsi paru secara progresif. Salah satu obat asma yang masih sering digunakan di Indonesia adalah aminofilin intravena. Aminofilin merupakan obat dengan rentang terapi sempit yang berisiko menyebabkan toksisitas obat, namun data perbandingan keuntungan efektivitas dan keamanan obat tersebut belum memadai. Penelitian ini bertujuan untuk mengetahui efektivitas aminofilin intravena pada pengobatan awal serangan asma berupa perbaikan gejala asma dan kejadian toksisitas terkait gejala yang muncul dan kadar teofilin dalam darah di suatu rumah sakit di Surabaya, Indonesia. Penelitian ini menggunakan metode pra-eksperimental yang dilaksanakan sejak 2014 hingga 2016. Sebanyak 27 pasien terlibat dalam penelitian ini. Terapi yang diberikan adalah aminofilin intravena selama satu jam. Metode sampling yang digunakan adalah consecutive sampling dengan teknik analisis deskriptif dan jum. Semua subjek penelitian menunjukkan perbaikan gejala serangan asma dengan terapi aminofilin intravena selama satu jam, dan tidak ada yang mengalami toksisitas karena kadar teofilin dalam darah di bawah rentang terapi. Aminofilin masih efektif dalam mengurangi gejala pada serangan asma dan tidak menunjukkan risiko toksisitas.Kata kunci: Aminofilin, efektivitas, serangan asma, toksisitas Effectiveness and Toxicity Risk of Intravenous Aminophylline in Exacerbation Asthma Treatment AbstractAsthma is a chronic inflammatory disease in the respiratory tract that has a considerable global prevalence. The worsening of asthma is an asthma attack that causes asthma symptoms to increase and decreased lung function progressively. One of the most commonly used asthma medications in Indonesia is intravenous aminophylline. Aminophylline is a drug with a narrow range of therapies that is at risk of causing drug toxicity, but the comparative data on the efficacy and safety benefits of the drug are inadequate. This study aimed to determine the effectiveness of aminophylline intravenously in the early treatment of asthma attacks in the form of improvements in asthma symptoms and toxicity events related to the symptoms that appear and blood theophylline levels in a hospital in Surabaya, Indonesia. This study used a pre-experimental method which was carried out from 2014 to 2016. A total of twenty seven patients were involved in the study. The therapy given was aminophylline intravenously for one hour. The sampling method used was consecutive sampling with descriptive analysis technique. All subjects showed improved symptoms of asthma attacks with intravenous aminophylline therapy for one hour, and none had toxicity due to theophylline levels in the blood below the therapeutic range. Aminophylline is still effective in reducing symptoms in asthma attacks and does not indic...

show abstract

Post-Therapy Leukocytosis Events After Intravenous Aminophylline Compared to the Nebulized Salbutamol in Asthma Exacerbations Patients

Cited by 4 publications

References 15 publications

Effects of nebulised beta-2 agonists on clinical observations in asthma exacerbations

Effects of nebulised beta-2 agonists on clinical observations in asthma exacerbations

Patterns of bronchodilator therapy in asthmatic outpatients

Effectiveness and Toxicity Risk of Intravenous Aminophylline in Exacerbation Asthma Treatment

Contact Info

Product

Resources

About